Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
    Meeting Abstract

    Makker, V.; Colombo, N.; Herraez, A. C.; Monk, B. J.; Mackay, H.; Santin, A. D.; Miller, D. S.; Moore, R. G.; Baron-Hay, S. E.; Ray-Coquard, I. L.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety
    Meeting Abstract

    Gonzalez Martin, A. J.; Pothuri, B.; Vergote, I. B.; Graybill, W.; Mirza, M. R.; Mccormick, C.; Lorusso, D.; Freyer, G.; Backes, F.; Baumann, K. H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)
    Meeting Abstract

    Moore, K. N.; Oza, A. M.; Colombo, N.; Oaknin, A.; Scambia, G.; Lorusso, D.; Banerjee, S.; Murphy, C.; Konner, J.; Lim, P.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
    Meeting Abstract

    Gelderblom, H.; Abdul Razak, A.; Martin-Broto, J.; Wilky, B. A.; Rutkowski, P.; Narasimhan, S.; Vallee, M.; Sharma, M.; Ruiz-Soto, R.; Sherman, M. L.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase Ib study of elimusertib (ATRi; BAY 1895344) in combination with niraparib (PARPi) in patients with advanced solid tumors
    Meeting Abstract

    Yap, T. A.; Konstantinopoulos, P.; Grisham, R. N.; Gupta, D.; Wilkinson, G.; Cao, A.; Jeffers, M.; Sharma, N.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
    Meeting Abstract

    DiSilvestro, P.; Banerjee, S.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M. L.; Lisyanskaya, A. S.; Floquet, A.; Leary, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
    Meeting Abstract

    Van Nieuwenhuysen, E.; O'Malley, D.; O'Cearbhaill, R. E.; Moore, K. N.; Hamilton, E. P.; Yeku, O.; Bouberhan, S.; Hou, J. Y.; Yoo, S. Y.; Brouwer-Visser, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
    Meeting Abstract

    McDermott, R. S.; van Tilburg, C.; Lin, J. J.; Kummar, S.; Tan, D. S. W.; Albert, C. M.; Berlin, J. D.; Lassen, U. N.; Doz, F.; Geoerger, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
    Meeting Abstract

    Italiano, A.; Drilon, A. E.; Shen, L.; Hong, D. S.; van Tilburg, C.; Tan, D. S. W.; Lin, J. J.; Kummar, S.; Doz, F.; Geoerger, B.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy of BRAF inhibitor FORE8394 in BRAF V600+ patients
    Meeting Abstract

    Sherman, E. J.; Tsai, F.; Janku, F.; Allen, C.; Yaeger, R.; Ammakkanavar, N.; Butowski, N.; Michelson, G.; Paz, M.; Tussay-Lindenberg, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save